Activation of p53 alone may often be insufficient to engage apoptosis but instead induce cell-cycle regulatory proteins to orchestrate reversible cell cycle arrest, protecting tumor cells from apoptotic cell death and plausibly attests to the limited clinical efficacy of monotherapy MDM2 inhibitors. The gene discussed is TP53; the disease is neoplasm.